Abstract
CHMP2B mutations are a rare cause of autosomal dominant frontotemporal dementia (FTD). The best studied example is frontotemporal dementia linked to chromosome 3 (FTD-3) which occurs in a large Danish family, with a further CHMP2B mutation identified in an unrelated Belgian familial FTD patient. These mutations lead to C-terminal truncations of the CHMP2B protein and we will review recent advances in our understanding of the molecular effects of these mutant truncated proteins on vesicular fusion events within the endosome-lysosome and autophagy degradation pathways. We will also review the clinical features of FTD caused by CHMP2B truncation mutations as well as new brain imaging and neuropathological findings. Finally, we collate the current data on CHMP2B missense mutations, which have been reported in FTD and motor neuron disease.
Keywords: Frontotemporal dementia, CHMP2B, endosome, lysosome, autophagy, brain imaging, neuropathology, CBD, FTLD-TDP, CHMP2BIntron5, CHMP2BDelta10, CHMP2BQ165X, lateral preponderance, MND, neurotransmitter receptors
Current Alzheimer Research
Title: Frontotemporal Dementia Caused by CHMP2B Mutations
Volume: 8 Issue: 3
Author(s): A. M. Isaacs, P. Johannsen, I. Holm, J. E. Nielsen and FReJA Consortium
Affiliation:
Keywords: Frontotemporal dementia, CHMP2B, endosome, lysosome, autophagy, brain imaging, neuropathology, CBD, FTLD-TDP, CHMP2BIntron5, CHMP2BDelta10, CHMP2BQ165X, lateral preponderance, MND, neurotransmitter receptors
Abstract: CHMP2B mutations are a rare cause of autosomal dominant frontotemporal dementia (FTD). The best studied example is frontotemporal dementia linked to chromosome 3 (FTD-3) which occurs in a large Danish family, with a further CHMP2B mutation identified in an unrelated Belgian familial FTD patient. These mutations lead to C-terminal truncations of the CHMP2B protein and we will review recent advances in our understanding of the molecular effects of these mutant truncated proteins on vesicular fusion events within the endosome-lysosome and autophagy degradation pathways. We will also review the clinical features of FTD caused by CHMP2B truncation mutations as well as new brain imaging and neuropathological findings. Finally, we collate the current data on CHMP2B missense mutations, which have been reported in FTD and motor neuron disease.
Export Options
About this article
Cite this article as:
M. Isaacs A., Johannsen P., Holm I., E. Nielsen J. and Consortium FReJA, Frontotemporal Dementia Caused by CHMP2B Mutations, Current Alzheimer Research 2011; 8(3) . https://dx.doi.org/10.2174/156720511795563764
DOI https://dx.doi.org/10.2174/156720511795563764 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
TNF-α Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets
Current Alzheimer Research Food Fortification with Omega-3 Fatty Acids; Microencapsulation as an Addition Method
Current Nutrition & Food Science Persons with Co-Existing Neurological Disorders: Risk Analysis, Considerations and Management in COVID-19 Pandemic
CNS & Neurological Disorders - Drug Targets Molecular Imaging of Neuropsychiatry and Boron Neutron Capture Therapy in Neuro-oncology
Current Molecular Imaging (Discontinued) Imaging Neuroinflammation in Ischemic Stroke and in the Atherosclerotic Vascular Disease
Current Vascular Pharmacology Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease
Current Genomics Evidence for Predominance of CCR5-Using HIV-1 Strains During Highly Active Antiretroviral Therapy
Current HIV Research Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design Noradrenergic Regulation of Glial Activation: Molecular Mechanisms and Therapeutic Implications
Current Neuropharmacology SPECT Radiopharmaceuticals for Dementia
Current Radiopharmaceuticals Editorial [Hot Topic: Nutrition and Alzheimers Disease: Is There Any Connection? (Guest Editor: C. Ramassamy)]
Current Alzheimer Research Targeting Nitrosative Stress for Neurovascular Protection: New Implications in Brain Diseases
Current Drug Targets Effects of 8-Residue Beta Sheet Breaker Peptides on Aged Aβ40 – Induced Memory Impairment and Aβ40 Expression in Rat Brain and Serum Following Intraamygdaloid Injection
Current Alzheimer Research Saving the Ischemic Penumbra: Potential Role for Statins and Phosphodiesterase Inhibitors
Current Vascular Pharmacology HIV1-Human Protein-Protein Interaction Prediction (HHPPIP) Methodology: An FP-Growth Based Association Rule Mining Approach
Current Bioinformatics The Effects of Prostaglandin E-1 in Patients with Intermittent Claudication
Cardiovascular & Hematological Disorders-Drug Targets Brain Perfusion In Sepsis
Current Vascular Pharmacology Quantitative Machine Learning Analysis of Brain MRI Morphology throughout Aging
Current Aging Science Genes and Hypertension
Current Pharmaceutical Design The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued)